Дедов И.И., Шестакова М.В., Викулова О.К. и др. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г. Сахарный диабет. 2018;21(3):144-159. doi: 10.14341/DM9686..
DOI: 10.14341/DM9686
Шляхто Е.В., Шестакова М.В. Снижение риска сердечно-сосудистой смерти у пациентов с сахарным диабетом 2 типа и подтвержденными сердечно-сосудистыми заболеваниями. Российский кардиологический журнал. 2018;(9):58-64. doi: 10.15829/1560-4071-2018-9-58-64..
DOI: 10.15829/1560-4071-2018-9-58-64
Htay T., Soe K., Lopez-Perez A., Doan A.H., Romagosa M.A., Aung K. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. Current Cardiology Reports. 2019;21(6):45. doi: 10.1007/s11886-019-1133-9..
DOI: 10.1007/s11886-019-1133-9
Никонова Л.В., Дорошкевич И.П. Физиологические эффекты инкретинов при сахарном диабете 2 типа. Журнал Гродненского государственного медицинского университета. 2013;(1):18-21. Режим доступа: http://elib.grsmu.by/handle/files/4037.http://elib.grsmu.by/handle/files/4037
Никонова Л.В., Дорошкевич И.П. Физиологические эффекты инкретинов при сахарном диабете 2 типа. Журнал Гродненского государственного медицинского университета. 2013;(1):18-21. Режим доступа: http://elib.grsmu.by/handle/files/4037.http://elib.grsmu.by/handle/files/4037
Moore B., Edie E., Abram J. On the treatment of diabetes mellitus by acid extract of duodenal mucosa membrane. Biochem J. 1906;1(1):28–38. doi: 10.1042/bj0010028..
DOI: 10.1042/bj0010028
Brown J., Dryburgh J. A gastric inhibitory polypeptide. II. The complete amino acid sequence. Can J Biochem. 1971;49(8):867–872. doi: 10.1139/o71-122..
DOI: 10.1139/o71-122
Baggio L.L., Drucker D.J. Biology of incretins: GLP‐1 and GIP. Gastroenterology. 2007;132(6):2131‐2157. doi: 10.1053/j.gastro.2007.03.054..
DOI: 10.1053/j.gastro.2007.03.054
Vilsbøll T., Holst J.J. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia. 2004;47(3):357-366. doi: 10.1007/s00125-004-1342-6..
DOI: 10.1007/s00125-004-1342-6
Hare K.J., Knop F.K., Asmar M. et al. Preserved inhibitory potency of GLP‐1 on glucagon secretion in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94(12):4679–4687. doi: 10.1210/jc.2009-0921..
DOI: 10.1210/jc.2009-0921
Holst J.J. On the physiology of GIP and GLP‐1. Horm Metab Res. 2004;36(11-12):747‐754. doi: 10.1055/s-2004-826158..
DOI: 10.1055/s-2004-826158
Holst J.J. On the physiology of GIP and GLP‐1. Horm Metab Res. 2004;36(11-12):747‐754. doi: 10.1055/s-2004-826158..
DOI: 10.1172/JCI116186
Nauck M.A., Heimesaat M.M., Ørskov C. et al. Preserved incretin activity of glucagon‐like peptide 1 [7‐36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type‐2 diabetes mellitus. J Clin Invest. 1993;91(1):301–307. doi: 10.1172/JCI116186..
DOI: 10.1172/JCI116186
Nauck M.A., Heimesaat M.M., Ørskov C. et al. Preserved incretin activity of glucagon‐like peptide 1 [7‐36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type‐2 diabetes mellitus. J Clin Invest. 1993;91(1):301–307. doi: 10.1172/JCI116186..
DOI: 10.1210/jcem-24-10-1076
Elrick H., Stimmler L., Hlad Jr. C.J., Arai Y. Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;(24):1076–1082. doi: 10.1210/jcem-24-10-1076..
DOI: 10.1210/jcem-24-10-1076
Elrick H., Stimmler L., Hlad Jr. C.J., Arai Y. Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;(24):1076–1082. doi: 10.1210/jcem-24-10-1076..
DOI: 10.1007/s00125-002-1028-x
Gault V.A., O’Harte F.P., Harriott P. et al. Effects of the novel (Pro3)GIP antagonist and exendin(9‐39)amide on GIP‐ and GLP‐1‐ induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia. 2003;46(2):222‐230. doi: 10.1007/s00125-002-1028-x..
DOI: 10.1007/s00125-002-1028-x
Gault V.A., O’Harte F.P., Harriott P. et al. Effects of the novel (Pro3)GIP antagonist and exendin(9‐39)amide on GIP‐ and GLP‐1‐ induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia. 2003;46(2):222‐230. doi: 10.1007/s00125-002-1028-x..
DOI: 10.1124/pr.108.000604
Kim W., Egan J. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60(4):470-512. doi: 10.1124/pr.108.000604..
DOI: 10.1124/pr.108.000604
Kim W., Egan J. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60(4):470-512. doi: 10.1124/pr.108.000604..
DOI: 10.1385/CBB:40:3:65
Bulotta A., Farilla L., Hui H. et al. The role of GLP-1 in the regulation of islet cell mass. Cell Biochem Biophys. 2004;(40):65–77. doi:10.1385/CBB:40:3:65..
DOI: 10.1385/CBB:40:3:65
Bulotta A., Farilla L., Hui H. et al. The role of GLP-1 in the regulation of islet cell mass. Cell Biochem Biophys. 2004;(40):65–77. doi:10.1385/CBB:40:3:65..
DOI: 10.1093/hmg/ddp178
Shu L., Matveyenko A.V., Kerr-Conte J., Cho J.H., McIntosh C.H., Maedler K. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet. 2009;18(13):2388-2399. doi: 10.1093/hmg/ddp178..
DOI: 10.1093/hmg/ddp178http://www.mif-ua.com/archive/article/25195
Аметов А.С., Карпова Е.В. Новая возможность достижения цели лечения пациентов с сахарным диабетом 2-го типа. Международный эндокринологический журнал. 2011;8(40):10-15. Режим доступа: http://www.mif-ua.com/archive/article/25195..
DOI: 10.1016/j.bbrc.2018.03.199http://www.mif-ua.com/archive/article/25195
Kumari P., Nakata M., Zhang B.Y., Otgon-Uul Z., Yada T. GLP-1 receptor agonist liraglutide exerts central action to induce β-cell proliferation through medulla to vagal pathway in mice. Biochem Biophys Res Commun. 2018;499(3):618-625. doi: 10.1016/j.bbrc.2018.03.199..
DOI: 10.1016/j.bbrc.2018.03.199
Kumari P., Nakata M., Zhang B.Y., Otgon-Uul Z., Yada T. GLP-1 receptor agonist liraglutide exerts central action to induce β-cell proliferation through medulla to vagal pathway in mice. Biochem Biophys Res Commun. 2018;499(3):618-625. doi: 10.1016/j.bbrc.2018.03.199..
DOI: 10.1016/0167-0115(96)00135-8
Raufman J.P. Bioactive peptides from lizard venoms. Regulatory Peptides. 1996;61(1):1–18. doi: 10.1016/0167-0115(96)00135-8..
DOI: 10.1016/0167-0115(96)00135-8
Raufman J.P. Bioactive peptides from lizard venoms. Regulatory Peptides. 1996;61(1):1–18. doi: 10.1016/0167-0115(96)00135-8..
DOI: 10.1111/j.1463-1326.2011.01357.x
Madsbad S., Kielgast U., Asmar M., Deacon C.F., Torekov S.S., Holst J.J. An overview of onceweekly glucagon-like peptide-1 receptor agonists– available efficacy and safety data and perspectives for the future. Diabetes Obes Metab. 2011;13(5):394-407. doi: 10.1111/j.1463-1326.2011.01357.x..
DOI: 10.1111/j.1463-1326.2011.01357.x
Madsbad S., Kielgast U., Asmar M., Deacon C.F., Torekov S.S., Holst J.J. An overview of onceweekly glucagon-like peptide-1 receptor agonists– available efficacy and safety data and perspectives for the future. Diabetes Obes Metab. 2011;13(5):394-407. doi: 10.1111/j.1463-1326.2011.01357.x..
DOI: 10.1007/s00125-018-4729-5
Davies M.J., D’Alessio D.A., Fradkin J. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461-2498. doi: 10.1007/s00125-018-4729-5..
DOI: 10.1007/s00125-018-4729-5
Davies M.J., D’Alessio D.A., Fradkin J. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461-2498. doi: 10.1007/s00125-018-4729-5..
DOI: 10.1056/NEJMoa1603827
Marso S.P., Daniels G.H., Brown-Frandsen K., et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;(375):311-322. doi: 10.1056/NEJMoa1603827..
DOI: 10.1056/NEJMoa1603827
Marso S.P., Daniels G.H., Brown-Frandsen K., et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;(375):311-322. doi: 10.1056/NEJMoa1603827..
DOI: 10.1016/j.cmet.2018.03.001
Drucker D.J. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018;27(4):740-756. doi: 10.1016/j.cmet.2018.03.001..
DOI: 10.1016/j.cmet.2018.03.001
Drucker D.J. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018;27(4):740-756. doi: 10.1016/j.cmet.2018.03.001..
DOI: 10.1016/j.tem.2018.01.011
Lim S., Kim K.M., Nauck M.A. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns. Trends in Endocrinology & Metabolism. 2018;29(4):238-248. doi: 10.1016/j.tem.2018.01.011..
DOI: 10.1016/j.tem.2018.01.011
Lim S., Kim K.M., Nauck M.A. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns. Trends in Endocrinology & Metabolism. 2018;29(4):238-248. doi: 10.1016/j.tem.2018.01.011..
DOI: 10.1056/NEJMoa1607141
Marso S.P., Bain S.C., Consoli A., et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. doi: 10.1056/NEJMoa1607141..
DOI: 10.1056/NEJMoa1607141
Marso S.P., Bain S.C., Consoli A., et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. doi: 10.1056/NEJMoa1607141..
DOI: 10.1056/NEJMoa1612917
Holman R.R., Bethel M.A., Mentz R.J., Thompson V.P., Lokhnygina Y., Buse J.B., et al. EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(13):1228-1239. doi: 10.1056/NEJMoa1612917..
DOI: 10.1056/NEJMoa1612917
Holman R.R., Bethel M.A., Mentz R.J., Thompson V.P., Lokhnygina Y., Buse J.B., et al. EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(13):1228-1239. doi: 10.1056/NEJMoa1612917..
DOI: 10.1016/S0140-6736(18)32261-X
Hernandez A.F., Green J.B., Janmohamed S., D’Agostino R.B. Sr., Granger C.B., Jones N.P., et al. Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–1529. doi: 10.1016/S0140-6736(18)32261-X..
DOI: 10.1016/S0140-6736(18)32261-X
Hernandez A.F., Green J.B., Janmohamed S., D’Agostino R.B. Sr., Granger C.B., Jones N.P., et al. Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–1529. doi: 10.1016/S0140-6736(18)32261-X..
DOI: 10.1155/2018/1631263
Seferovic J.P., Bentley-Lewis R., Claggett B., Diaz R., Gerstein H.C., Kober L.V. et al. Retinopathy, neuropathy, and subsequent cardiovascular events in patients with Type 2 diabetes and acute coronary syndrome in the ELIXA: the importance of disease duration. J Diabet Res. 2018:1631263. doi: 10.1155/2018/1631263..
DOI: 10.1155/2018/1631263
Seferovic J.P., Bentley-Lewis R., Claggett B., Diaz R., Gerstein H.C., Kober L.V. et al. Retinopathy, neuropathy, and subsequent cardiovascular events in patients with Type 2 diabetes and acute coronary syndrome in the ELIXA: the importance of disease duration. J Diabet Res. 2018:1631263. doi: 10.1155/2018/1631263..
DOI: 10.1111/dom.13028
Gerstein H.C., Colhoun H.M., Dagenais G.R., et al. REWIND Trial Investigators. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20(1):42-49. doi: 10.1111/dom.13028..
DOI: 10.1111/dom.13028
Gerstein H.C., Colhoun H.M., Dagenais G.R., et al. REWIND Trial Investigators. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20(1):42-49. doi: 10.1111/dom.13028..
DOI: 10.2147/DMSO.S134960
Kugler A.J., Thiman M.L. Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data. Diabetes Metab Syndr Obes. 2018;(11):187-197. doi: 10.2147/DMSO.S134960..
DOI: 10.2147/DMSO.S134960
Kugler A.J., Thiman M.L. Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data. Diabetes Metab Syndr Obes. 2018;(11):187-197. doi: 10.2147/DMSO.S134960..
DOI: 10.1016/S0140-6736(19)31149-3
Gerstein H.C., Colhoun H.M., Dagenais G.R., Diaz R., Pais P. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo- controlled trial. The Lancet. 2019;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3..
DOI: 10.1016/S0140-6736(19)31149-3
Gerstein H.C., Colhoun H.M., Dagenais G.R., Diaz R., Pais P. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo- controlled trial. The Lancet. 2019;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3..
DOI: 10.1016/S0140-6736(19)31150-X
Gerstein H.C., Colhoun H.M., Dagenais G.R., Diaz R., Pais P. et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebocontrolled trial. The Lancet. 2019;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X..
DOI: 10.1016/S0140-6736(19)31150-X